Skip to main content

Table 1 Patient background

From: Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens

  Total (n=60) HLA-A24 (+) (n=35) HLA A24 (-) (n=25)  
Age(year) 61.8±7.6 62.3±7.1 61.1±8.2 NS
Male: Female 53/7 32/3 21/4 NS
Prior therapy     
Operation 29(48%) 19(54%) 10(40%) NS
Radiation 48(80%) 26(74%) 22(88%) NS
Chemotheraphy     
5FU 59(98%) 35(100%) 24(96%) NS
CDDP 58(97%) 33(94%) 23(92%) NS
Docetaxel 54(90%) 31(91%) 23(92%) NS
  1. NS not significant between the HLA-A24(+) and HLA-A24(-) group.